Showing results (341-350 of 348) with videos related to
Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 348 results.
Critical Care (London, England)|September 12, 2020
Cross-sectional study for the clinical application of extracorporeal membrane oxygenation in Mainland China, 2018Wei Cheng, Xu-Dong Ma, Long-Xiang Su, et al.Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|March 31, 2026
The 2025 guidance on the surveillance and control of Candida infections: Recommendations from the China invasive fungal surveillance net (CHIF-NET) study groupMeng Xiao, Li Zhang, He Wang, et al.Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.Military Medical Research|December 25, 2022
Expert consensus on the monitoring and treatment of sepsis-induced immunosuppressionFei Pei, Ren-Qi Yao, Chao Ren, et al.Pageof 35